← Leaderboards
John R Guy
University Of Florida
$21,490,889
Attributed
$22,240,696
Total exposure
8
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.4M · FY2005–19$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$22,240,696 · 8
By mechanism
R01$10,205,702 · 4
R24$6,233,443 · 2
U10$5,801,550 · 1
UG1$1 · 1
Top collaborators
- William W Hauswirth1 shared
- Martha D. Neuringer1 shared
Most similar at University Of Florida
Same institution · by research overlap
- Alfred S Lewin$10,095,035
- William W Hauswirth$34,023,360
Others in their field
Top investigators on “Gene Therapy”
- David Heimbrook · Leidos Biomedical Research, Inc.$164,199,916
- Gregory H Reaman · National Childhood Cancer Foundation$155,841,493
- Randall J Bateman · Washington University$122,781,098
- Eric Martin McDade · Washington University$94,632,845
- Ronald G Crystal · Weill Medical College Of Cornell Univ$82,649,124
- Robert B. Diasio · University Of Alabama At Birmingham$73,470,685
Research focus
Gene TherapyOptic NerveMitochondriaLeber&AposGenesBlindnessApoptosisComplexMitochondrial DnaCellsS Hereditary Optic NeuropathyAffectMutateMutantMutationVectorAnimal ModelMitochondrial DiseasesPathogenesisOptic DiskRetinaSwellingOptic Nerve DisorderPrevent
Grant awards (42)
Mito-Targeted AAV to treat Leber Hereditary Optic Neuropathy caused by ND4 mutations$1,124,711
R24 · FY2019 · EY · contact PI
Intravenous MitoTargeted AAV9 Gene Therapy for Treatment of Visual Loss and Encephalopathy in Leigh Syndrome and NARP$383,750
R01 · FY2019 · EY · contact PI
Lebers Hereditary Optic Neuropathy: Gene Therapy$1
UG1 · FY2019 · EY · contact PI
Intravenous MitoTargeted AAV9 Gene Therapy for Treatment of Visual Loss and Encephalopathy in Leigh Syndrome and NARP$383,750
R01 · FY2018 · EY · contact PI
Modification of AdenoAssociated Virus to Deliver DNA Directly to Mitochondria$368,148
R01 · FY2018 · EY · contact PI
Leber's Hereditary Optic Neuropathy: Gene Therapy Clinical Trial$1
U10 · FY2018 · EY · contact PI
Leber's Hereditary Optic Neuropathy: Gene Therapy Clinical Trial$1,160,639
U10 · FY2017 · EY · contact PI
Intravenous MitoTargeted AAV9 Gene Therapy for Treatment of Visual Loss and Encephalopathy in Leigh Syndrome and NARP$383,750
R01 · FY2017 · EY · contact PI
Modification of AdenoAssociated Virus to Deliver DNA Directly to Mitochondria$369,683
R01 · FY2017 · EY · contact PI
Leber's Hereditary Optic Neuropathy: Gene Therapy Clinical Trial$1,367,380
U10 · FY2016 · EY · contact PI
Modification of AdenoAssociated Virus to Deliver DNA Directly to Mitochondria$549,051
R01 · FY2016 · EY · contact PI
Transgenic Mitomice Models for Treatment of Blinding Diseases$383,750
R01 · FY2016 · EY · contact PI
Leber's Hereditary Optic Neuropathy: Gene Therapy Clinical Trial$2,050,445
U10 · FY2015 · EY · contact PI
Transgenic Mitomice Models for Treatment of Blinding Diseases$376,075
R01 · FY2015 · EY · contact PI
Leber's Hereditary Optic Neuropathy: Gene Therapy Clinical Trial$1,223,085
U10 · FY2014 · EY · contact PI
Transgenic Mitomice Models for Treatment of Blinding Diseases$376,075
R01 · FY2014 · EY · contact PI
Transgenic Mitomice Models for Treatment of Blinding Diseases$383,438
R01 · FY2013 · EY · contact PI
Leber Hereditary Optic Neuropathy: Gene Therapy Trial$931,528
R24 · FY2012 · EY · contact PI
Leber Hereditary Optic Neuropathy: Gene Therapy Trial$1,084,780
R24 · FY2011 · EY · contact PI
Modification of AdenoAssociated Virus to deliver DNA directly to Mitochondria$361,086
R01 · FY2011 · EY · contact PI
Experimental Optic Neuritis: Gene Therapy$360,330
R01 · FY2011 · EY · contact PI
Leber Hereditary Optic Neuropathy: Gene Therapy Trial$862,515
R24 · FY2010 · EY · contact PI
Leber Hereditary Optic Neuropathy: Gene Therapy Trial$473,006
R24 · FY2010 · EY · contact PI
Experimental Optic Neuritis: Gene Therapy$375,418
R01 · FY2010 · EY · contact PI
Modification of AdenoAssociated Virus to deliver DNA directly to Mitochondria$230,919
R01 · FY2010 · EY · contact PI
Leber Hereditary Optic Neuropathy: Gene Therapy Trial$885,450
R24 · FY2009 · EY · contact PI
Modification of AdenoAssociated Virus to deliver DNA directly to Mitochondria$380,069
R01 · FY2009 · EY · contact PI
Experimental Optic Neuritis: Gene Therapy$379,283
R01 · FY2009 · EY · contact PI
Leber Hereditary Optic Neuropathy: Gene Therapy Trial$871,453
R24 · FY2008 · EY · contact PI
Experimental Optic Neuritis: Gene Therapy$389,423
R01 · FY2008 · EY · contact PI
Modification of AdenoAssociated Virus to deliver DNA directly to Mitochondria$383,591
R01 · FY2008 · EY · contact PI
Modification of AdenoAssociated Virus to deliver DNA directly to Mitochondria$366,250
R01 · FY2007 · EY · contact PI
LEBER HEREDITARY OPTIC NEUROPATHY: GENE THERAPY$284,162
R01 · FY2006 · EY · contact PI
LEBER HEREDITARY OPTIC NEUROPATHY: GENE THERAPY$291,000
R01 · FY2005 · EY
OPTIC NEURITIS: GENE THERAPY$291,000
R01 · FY2004 · EY
LEBER HEREDITARY OPTIC NEUROPATHY: GENE THERAPY$291,000
R01 · FY2004 · EY
LEBER HEREDITARY OPTIC NEUROPATHY: GENE THERAPY$290,167
R01 · FY2003 · EY
OPTIC NEURITIS: GENE THERAPY$290,000
R01 · FY2003 · EY
OPTIC NEURITIS: GENE THERAPY$290,000
R01 · FY2002 · EY
LEBER HEREDITARY OPTIC NEUROPATHY: GENE THERAPY$356,288
R01 · FY2001 · EY
OPTIC NEURITIS: GENE THERAPY$290,000
R01 · FY2001 · EY
LEBER HEREDITARY OPTIC NEUROPATHY: GENE THERAPY$348,246
R01 · FY2000 · EY